Michelle Robertson
Director of Finance/CFO chez GERON CORPORATION
Fortune : 791 046 $ au 31/03/2024
Profil
Michelle Robertson is currently an Independent Director at Verastem, Inc. and will be the Chief Financial Officer, Treasurer & Executive VP at Geron Corp.
starting in 2023.
She was previously the Treasurer, Chief Financial & Accounting Officer at Momenta Pharmaceuticals, Inc. from 2017 to 2020, Head-Financial Planning & Analysis at Ironwood Pharmaceuticals, Inc. from 2012 to 2015, Vice President-Oncology Finance at Baxalta, Inc. in 2015-2016, and the Chief Financial Officer, Treasurer & Executive VP at Editas Medicine, Inc. from 2020 to 2023.
Ms. Robertson received her undergraduate degree from Bentley University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EDITAS MEDICINE, INC.
0,13% | 11/05/2023 | 106 610 ( 0,13% ) | 791 046 $ | 31/03/2024 |
GERON CORPORATION
-.--% | 01/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
VERASTEM, INC.
-.--% | 11/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Michelle Robertson
| Sociétés | Poste | Début |
|---|---|---|
| VERASTEM, INC. | Director/Board Member | 15/11/2021 |
| GERON CORPORATION | Director of Finance/CFO | 25/09/2023 |
Anciens postes connus de Michelle Robertson
| Sociétés | Poste | Fin |
|---|---|---|
| EDITAS MEDICINE, INC. | Director of Finance/CFO | 17/05/2023 |
| MOMENTA PHARMACEUTICALS, INC. | Director of Finance/CFO | 08/01/2020 |
| BAXALTA INC | Corporate Officer/Principal | 01/01/2016 |
| IRONWOOD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2015 |
Formation de Michelle Robertson
| Bentley University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| GERON CORPORATION | Health Technology |
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| VERASTEM, INC. | Health Technology |
| EDITAS MEDICINE, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
